JPS5844985B2 - Reagent for hemoglobin measurement - Google Patents
Reagent for hemoglobin measurementInfo
- Publication number
- JPS5844985B2 JPS5844985B2 JP4090976A JP4090976A JPS5844985B2 JP S5844985 B2 JPS5844985 B2 JP S5844985B2 JP 4090976 A JP4090976 A JP 4090976A JP 4090976 A JP4090976 A JP 4090976A JP S5844985 B2 JPS5844985 B2 JP S5844985B2
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- hemoglobin
- sodium azide
- present
- hemoglobin measurement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Description
【発明の詳細な説明】 本発明はヘモグロビンを測定する為の試薬に関する。[Detailed description of the invention] The present invention relates to a reagent for measuring hemoglobin.
ヘモグロビンの測定は血液疾患の診断に欠くべからざる
もので、近年国際標準法として採用されるに至ったいわ
ゆるシアンメトヘモグロビン法が一般に用いられている
。Measurement of hemoglobin is essential for the diagnosis of blood diseases, and the so-called cyanmethemoglobin method, which has recently been adopted as an international standard method, is generally used.
この方法は精度も高く簡便であるので現在量も優れた方
法であるといえる。This method has high accuracy and is simple, so it can be said that it is an excellent method in terms of current quantity.
しかしながら、この方法で用いるシアン化カリウムトよ
びフェリシアン化カリウムが劇毒物であるので、試薬の
調製の際の取扱いないし廃水処理等に訟いて危険性を有
し、無公害の改良方法の研究が望１れている。However, since the potassium cyanide and potassium ferricyanide used in this method are highly toxic, there is a danger in handling them during the preparation of the reagents and in treating wastewater, and there is a need for research into improved methods that are non-polluting. There is.
本発明者らはこのような現況に鑑み、種々検討の末、安
全で精度も高い測定法を見出し本発明を完成した。In view of the current situation, the present inventors, after various studies, have found a safe and highly accurate measuring method and have completed the present invention.
すなわち、本発明はｐ Ｈ７，０〜８．０の緩衝液にア
ルカリ金属亜硝酸塩を（１２〜１．０％およびナトリウ
ムアジドを０．０８％〜０．１２％配合せしめたヘモグ
ロビン測定用試薬である。That is, the present invention is a hemoglobin measuring reagent containing alkali metal nitrite (12-1.0%) and sodium azide (0.08%-0.12%) in a pH 7.0-8.0 buffer. be.
本発明の試薬を用いることによって血液ヘモグロビンは
アルカリ金属亜硝酸塩によりメトヘモグロビンに変り、
更にナトリウムアジドによってアジドメトヘモグロビン
に定量的に変換される。By using the reagent of the present invention, blood hemoglobin is converted to methemoglobin by an alkali metal nitrite,
Furthermore, it is quantitatively converted to azidomethemoglobin by sodium azide.
そしてこのアジドメトヘモグロビンが５４０ ｍｍに特
異吸収を示すので、光学的にヘモグロビン量を測定する
ことができる。Since this azidomethemoglobin exhibits specific absorption at 540 mm, the amount of hemoglobin can be measured optically.
本発明の組成物を調製するに当ってアルカリ金属亜硝酸
塩とナトリウムアジドの配合比は略８：１程度が好１し
く、用いられる緩衝液は中性ないし弱アルカリ性のもの
であればアジドメトヘモグロビンを効率よく生成させ旦
つ安定に保つことができるので、例えばトリス−クエン
酸−塩酸緩衝液等のｐ、Ｈ７，０〜８．０を示す種々の
緩衝液が使用される。In preparing the composition of the present invention, the blending ratio of alkali metal nitrite and sodium azide is preferably about 8:1, and if the buffer used is neutral or weakly alkaline, azidomethemoglobin Various buffers having a pH of 7.0 to 8.0, such as Tris-citric acid-hydrochloric acid buffer, are used because they can efficiently produce and simultaneously maintain stability.
尚、亜硝酸ナトリウムの安定性の点から、これを錠剤化
し、用時ナトリウムアジドー緩衝液に溶解せしめる方法
を採用することができる。In addition, from the viewpoint of the stability of sodium nitrite, it is possible to adopt a method in which it is made into tablets and dissolved in a sodium azide buffer before use.
亜硝酸ナトリウムの成型には本発明に影響を与えない不
活性な担体が用いられ常法により成型されるが、塩化ナ
トリウムを賦形剤として用いることにより、ナトリウム
アジド−緩衝液中に添加された界面活性剤の力価を増強
せしめ、透明化と迅速転化を良好ならしめることができ
るので特に好ｌしい。Sodium nitrite is molded by a conventional method using an inert carrier that does not affect the present invention, but by using sodium chloride as an excipient, it is added to the sodium azide buffer solution. It is particularly preferred because it can enhance the potency of the surfactant and improve transparency and rapid conversion.
実施例 １
アジ化ナトリウム１ｇ・亜硝酸ナトリウム８ｇ・塩化ナ
トリウム４，９＄−よびステロツクスＳＥ（モンサント
ケ□カルカンパニー製）０．５ｍ６ をトリス（ハイド
ロキシ−アミノメタン）−クエン酸緩衝液（ｐＨ７，５
）に溶かし、全量を１０１００Ｏとする。Example 1 1 g of sodium azide, 8 g of sodium nitrite, 4.9 $ of sodium chloride, and 0.5 m6 of Stelotux SE (manufactured by Monsanto Chemical Company) were added to a tris(hydroxy-aminomethane)-citrate buffer (pH 7, 5
) and make the total amount 10100O.
とのもの５配を試験管にとり、濃度変化させたヒト全血
又は精製したヒト酸素ヘモグロビン０．０２７ｎｌを加
え、２５°Ｃ又は３７℃で１０分間インキュベーション
を行なう。Five volumes of the same were placed in a test tube, 0.027 nl of human whole blood or purified human oxyhemoglobin of varying concentrations was added, and the mixture was incubated at 25°C or 37°C for 10 minutes.
所定時間終了後、水又は試薬盲検を対照として局長１０
ｍｍのセルを用い波長５４１ｍｍに督ける吸光度を測
定する。After the predetermined time, the director 10
The absorbance at a wavelength of 541 mm is measured using a 541 mm cell.
結果を図−１に示す。The results are shown in Figure 1.
実施例 ２
アジ化ナトリウム５ｍおよびステロソクスＳＥを含むト
リス（ハイドロキシ−アミノメタン）−クエン酸緩衝液
（ｐＨ７，ｊ） ５ ｍｌに１銑中亜硝酸ナトリウム
４０７ｎｇ・塩化ナトリウム２０階・マンニット３５Ｔ
ｎｇｂよびポリエチレングリコール・６０００５ｄを含
む錠剤１錠を溶解する。Example 2 5 ml of Tris (hydroxy-aminomethane)-citrate buffer (pH 7, j) containing 5 m of sodium azide and Sterosox SE, 407 ng of sodium nitrite, 20 molar sodium chloride, 35 T of mannitol in 1 pig iron
Dissolve one tablet containing ngb and polyethylene glycol 60005d.
このものにヒト全血又は精製したヒト酸素ヘモグロビン
０．０２７１１１を加え、実施例１と同様に操作したと
き、吸光度は実施例１と同様の値を示す。When human whole blood or purified human oxyhemoglobin 0.027111 was added to this and the same procedure as in Example 1 was performed, the absorbance showed the same value as in Example 1.
実施例 ３
実施例１又は実施例２の試薬組成と操作法を用いてヒト
全血５０例についてシアンメトヘモグロビン法との同時
測定を行ない相関性を求めた。Example 3 Using the reagent composition and operating method of Example 1 or 2, 50 cases of human whole blood were measured simultaneously with the cyanmethemoglobin method to determine the correlation.
結果を図−２に示す。The results are shown in Figure 2.
第１図は実施例１によるヘモグロビンの測定結果を示す
グラフであり、第２図は従来法と本発明による方法との
相関性を示すグラフである。FIG. 1 is a graph showing the measurement results of hemoglobin according to Example 1, and FIG. 2 is a graph showing the correlation between the conventional method and the method according to the present invention.
Claims (1)
ムアジド０．０８〜０゜１２％を含有するｐ Ｈ７，０
〜８．０の緩衝液からなるヘモグロビン測定用試薬。1 pH 7.0 containing 0.2-1.0% of alkali metal nitrite and 0.08-0.12% of sodium azide
A reagent for measuring hemoglobin consisting of a buffer solution of ~8.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4090976A JPS5844985B2 (en) | 1976-04-13 | 1976-04-13 | Reagent for hemoglobin measurement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4090976A JPS5844985B2 (en) | 1976-04-13 | 1976-04-13 | Reagent for hemoglobin measurement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS52124395A JPS52124395A (en) | 1977-10-19 |
| JPS5844985B2 true JPS5844985B2 (en) | 1983-10-06 |
Family
ID=12593623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4090976A Expired JPS5844985B2 (en) | 1976-04-13 | 1976-04-13 | Reagent for hemoglobin measurement |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5844985B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61107381U (en) * | 1984-12-20 | 1986-07-08 | ||
| WO2010067612A1 (en) * | 2008-12-11 | 2010-06-17 | 積水メディカル株式会社 | Method for pre-treating sample containing glycosylated hemoglobin |
| JPWO2011125484A1 (en) * | 2010-03-31 | 2013-07-08 | 積水メディカル株式会社 | Analysis method of hemoglobins |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2836865B2 (en) * | 1989-10-23 | 1998-12-14 | 東亜医用電子株式会社 | Reagents for measuring leukocytes and hemoglobin in blood |
-
1976
- 1976-04-13 JP JP4090976A patent/JPS5844985B2/en not_active Expired
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61107381U (en) * | 1984-12-20 | 1986-07-08 | ||
| WO2010067612A1 (en) * | 2008-12-11 | 2010-06-17 | 積水メディカル株式会社 | Method for pre-treating sample containing glycosylated hemoglobin |
| JP5574977B2 (en) * | 2008-12-11 | 2014-08-20 | 積水メディカル株式会社 | Pretreatment method for samples containing glycated hemoglobin |
| JPWO2011125484A1 (en) * | 2010-03-31 | 2013-07-08 | 積水メディカル株式会社 | Analysis method of hemoglobins |
| JP5875160B2 (en) * | 2010-03-31 | 2016-03-02 | 積水メディカル株式会社 | Analysis method of hemoglobins |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS52124395A (en) | 1977-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Burton | Formation constants for the complexes of adenosine di-or tri-phosphate with magnesium calcium or ions | |
| Riggs | The metamorphosis of hemoglobin in the bullfrog | |
| Morgan | Interactions of the histidine-rich glycoprotein of serum with metals | |
| Worwood et al. | Serum ferritin | |
| Miller | Use of dinitrosalicylic acid reagent for determination of reducing sugar | |
| Ohe et al. | Changes in pKa values of individual histidine residues of human hemoglobin upon reaction with carbon monoxide | |
| Searcy et al. | A study of the specificity of the Berthelot colour reaction | |
| Milgrom et al. | Preparation of antiglobulin sera | |
| Gutcho et al. | Cozymase-Assay of Diphosphopyridine Nucleotide Preparations | |
| JPS5844985B2 (en) | Reagent for hemoglobin measurement | |
| Brooks et al. | Labelling of inulin with radioactive iodine | |
| Bonnichsen | [138] Blood catalase | |
| McGregor et al. | Fetal tissue can synthesize a placental hormone. Evidence for chorionic gonadotropin beta-subunit synthesis by human fetal kidney. | |
| JPS6318706B2 (en) | ||
| Mokrasch | Spectrophotometric determination of phosphate in the presence of highly labile phosphorus compounds | |
| US3310382A (en) | Biuret reagent | |
| EP0433977B1 (en) | Method for optical measurement of bilirubin and reagent therefor | |
| Pätiälä | The amount of pyridine nucleotides (coenzymes I and II) in blood in experimental tuberculosis before and during isoniazid treatment | |
| Eppstein | Isolation and characterization of prolactin from porcine pituitaries | |
| Thompson | Modification of Michaelsson's method for the measurement of plasma total bilirubin | |
| JPH0358467B2 (en) | ||
| Thompson | Factor IX and prothrombin in amniotic fluid and fetal plasma: constraints on prenatal diagnosis of hemophilia B and evidence of proteolysis | |
| Jaselskis et al. | Xenic Acid Reactions with vic-Diols | |
| CN105242052A (en) | Serum copper detection kit suitable for full-automatic biochemical analyzer | |
| Hernandez et al. | The effect of carbonic anhydrase inhibition on the composition of urine and plasma of the alligator |